Seattle Genetics Inc (SGEN.OQ)

SGEN.OQ on NASDAQ Stock Exchange Global Select Market

36.25USD
27 Feb 2015
Change (% chg)

$-0.18 (-0.49%)
Prev Close
$36.43
Open
$36.76
Day's High
$37.86
Day's Low
$35.73
Volume
393,001
Avg. Vol
407,179
52-wk High
$55.90
52-wk Low
$30.10

SGEN.OQ

Chart for SGEN.OQ

About

Seattle Genetics, Inc. is biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS or brentuximab vedotin is approved by United States Food and Drug Administration (FDA) in two indications: the treatment of patients with Hodgkin... (more)

Overall

Beta: 1.43
Market Cap(Mil.): $4,538.15
Shares Outstanding(Mil.): 123.89
Dividend: --
Yield (%): --

Financials

  SGEN.OQ Industry Sector
P/E (TTM): -- 175.70 40.21
EPS (TTM): -0.62 -- --
ROI: -19.88 -2.61 16.34
ROE: -34.53 -4.38 17.27
Search Stocks

Glaxo scientists work to rebuild cancer line-up, funding uncertain

PHILADELPHIA - When GlaxoSmithKline agreed to sell its cancer drugs to Novartis in April, investors saw it as the death knell for an oncology business that languished well behind those of rivals.

05 Nov 2014

Glaxo scientists work to rebuild cancer line-up, funding uncertain

PHILADELPHIA, Nov 5 - When GlaxoSmithKline agreed to sell its cancer drugs to Novartis in April, investors saw it as the death knell for an oncology business that languished well behind those of rivals.

05 Nov 2014

Seattle Genetics and Takeda's cancer drug meets main trial goal

- Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer.

29 Sep 2014

UPDATE 1-Seattle Genetics and Takeda's cancer drug meets main trial goal

Sept 29 - Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer.

29 Sep 2014

Seattle Genetics, Takeda's cancer drug meets main goal in trial

Sept 29 - Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer.

29 Sep 2014

Genmab and Seattle Genetics in antibody drug agreement

COPENHAGEN, Sept 10 - Denmark's Genmab will pay Seattle Genetics $11 million to use its technology with Genmab's AXL antibody and future milestones and royalty payments, as a result of a potential product, could amount to $200 million, the companies said on Tuesday.

10 Sep 2014

Competitors

  Price Chg
Millennium Pharmacon Internationl Tbk PT (SDPC.JK) Rp. 88.00 +1.00
Eisai Co., Ltd (4523.T) ¥6,242 -58.00
Pfizer Inc. (PFE.N) $34.32 -0.27
Novartis AG (NOVN.VX) CHF97.45 -0.70
Merck & Co., Inc. (MRK.N) $58.54 -0.42
Bayer AG (BAYGn.DE) €132.05 +0.05
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €87.70 +0.16
GlaxoSmithKline plc (GSK.L) 1,541.50p -12.50
Eli Lilly and Co (LLY.N) $70.17 +0.14

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: S&P Capital IQ Factual Report
$150.00
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks